Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

De dna-gegevens van miljoenen gebruikers van dna-testdienst 23andMe zijn verkocht aan het TTAM Research Institute en komen toch niet in handen van farmabedrijf Regeneron. Het instituut wordt geleid do ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

De deal kwam voort uit een competitief biedingsproces tussen TTAM en Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), waarbij het bod van TTAM het eerdere bod van Regeneron van $ 256 mln. overtrof. De ...

DNA data saved: 23andMe co-founder Anne Wojcicki has bid $305 million through a nonprofit to acquire her bankrupt company, ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...